At a glance
- Originator UCB
- Class Antiglaucomas; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Angina pectoris
Most Recent Events
- 10 May 1996 New profile
- 10 May 1996 Discontinued-Preclinical for Angina pectoris in Belgium (Unknown route)